TherapeuticsMD Stock Volatility: Lawsuits for Recovery
The White Law Group is investigating potential securities claims involving brokers and financial advisors who may have unsuitably recommended TherapeuticsMD (TXMD) to investors.
TherapeuticsMD, a women’s healthcare company based in Florida, has a long history of public stock offerings—many of which were reportedly underwritten by Stifel, Nicolaus & Company, Incorporated.
Stock Performance and Volatility
TXMD has experienced significant volatility in recent years. The stock is currently trading around $1.12 per share (as of June 5, 2025), far below its 52-week high of $2.44 in early January. While TXMD is up more than 70% year-to-date, it remains down over 30% from the same time last year, reflecting ongoing instability and investor concerns.
In early June, TXMD shares reportedly dropped nearly 25% in a single trading session before bouncing back slightly.
Brokerage Firm Liability
Broker-dealers like Stifel that sell high-risk biotech stocks to retail investors have a duty to ensure investments are suitable based on the client’s risk tolerance, age, and financial situation. If a brokerage firm recommends speculative investments like TXMD without proper due diligence or in violation of its fiduciary duty, it may be held liable for losses through a FINRA arbitration claim.
Filing a Claim to Recover Losses
If your financial advisor overconcentrated your portfolio in high-risk biotech stocks such as TherapeuticsMD, or failed to disclose the risks, you may be able to recover your investment losses through FINRA arbitration.
For a free consultation with a securities attorney, please call The White Law Group at (888) 637-5510.
https://whitesecuritieslaw.com/
About Us
The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois and Seattle, Washington. We represent investors in FINRA arbitration claims against brokerage firms throughout the country.
Frequently Asked Questions (FAQs)
- Can I sue my broker for recommending TherapeuticsMD (TXMD)?
Yes, if your broker or financial advisor unsuitably recommended TherapeuticsMD or failed to adequately disclose the risks associated with investing in speculative biotech stocks, you may be eligible to file a FINRA arbitration claim to recover your losses. - Why is TherapeuticsMD considered a risky investment?
TherapeuticsMD is a micro-cap biotech company with a history of frequent public offerings and stock dilution. The company’s stock has shown extreme volatility, with sharp declines and gains that can significantly impact investor returns. These types of investments are typically suitable only for high-risk, speculative portfolios.
3. What role did Stifel play in TherapeuticsMD’s offerings?
Stifel, Nicolaus & Company, Incorporated acted as an underwriter for multiple public stock offerings of TherapeuticsMD between 2013 and 2015, helping the company raise tens of millions of dollars from investors. If a Stifel advisor recommended TXMD without assessing your risk profile, the firm may be liable for investment losses.
